Cutaneous leiomyomas lack estrogen and progesterone receptor immunoreactivity

Kent M. McGinley, Susan Bryant, Anthony A. Kattine, James F. Fitzgibbon, Paul Googe

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Gonadotropin-releasing hormone analog therapy is useful in treating uterine and some extrauterine smooth muscle tumors. These smooth muscle tumors have been demonstrated to have estrogen receptor and progesterone receptor immunoreactivity. The estrogen receptor and progesterone receptor immunoreactivity of smooth muscle tumors of the skin has not been reported. We evaluated 15 examples of cutaneous leiomyomas for estrogen receptor and progesterone receptor with ER-1D5 antibody and PGR-1AG antibody. None of the 15 cutaneous leiomyomas demonstrated positive staining by this method. The tumorigenesis of cutaneous leiomyomas does not appear to be related to estrogen or progesterone receptor-mediated effects.

Original languageEnglish (US)
Pages (from-to)241-245
Number of pages5
JournalJournal of Cutaneous Pathology
Volume24
Issue number4
DOIs
StatePublished - Jan 1 1997

Fingerprint

Leiomyoma
Progesterone Receptors
Smooth Muscle Tumor
Estrogen Receptors
Skin
Antibodies
Gonadotropin-Releasing Hormone
Carcinogenesis
Staining and Labeling
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Histology
  • Dermatology

Cite this

Cutaneous leiomyomas lack estrogen and progesterone receptor immunoreactivity. / McGinley, Kent M.; Bryant, Susan; Kattine, Anthony A.; Fitzgibbon, James F.; Googe, Paul.

In: Journal of Cutaneous Pathology, Vol. 24, No. 4, 01.01.1997, p. 241-245.

Research output: Contribution to journalArticle

McGinley, Kent M. ; Bryant, Susan ; Kattine, Anthony A. ; Fitzgibbon, James F. ; Googe, Paul. / Cutaneous leiomyomas lack estrogen and progesterone receptor immunoreactivity. In: Journal of Cutaneous Pathology. 1997 ; Vol. 24, No. 4. pp. 241-245.
@article{dc68c28e32314010a9b2a779b3204e69,
title = "Cutaneous leiomyomas lack estrogen and progesterone receptor immunoreactivity",
abstract = "Gonadotropin-releasing hormone analog therapy is useful in treating uterine and some extrauterine smooth muscle tumors. These smooth muscle tumors have been demonstrated to have estrogen receptor and progesterone receptor immunoreactivity. The estrogen receptor and progesterone receptor immunoreactivity of smooth muscle tumors of the skin has not been reported. We evaluated 15 examples of cutaneous leiomyomas for estrogen receptor and progesterone receptor with ER-1D5 antibody and PGR-1AG antibody. None of the 15 cutaneous leiomyomas demonstrated positive staining by this method. The tumorigenesis of cutaneous leiomyomas does not appear to be related to estrogen or progesterone receptor-mediated effects.",
author = "McGinley, {Kent M.} and Susan Bryant and Kattine, {Anthony A.} and Fitzgibbon, {James F.} and Paul Googe",
year = "1997",
month = "1",
day = "1",
doi = "10.1111/j.1600-0560.1997.tb01588.x",
language = "English (US)",
volume = "24",
pages = "241--245",
journal = "Journal of Cutaneous Pathology",
issn = "0303-6987",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Cutaneous leiomyomas lack estrogen and progesterone receptor immunoreactivity

AU - McGinley, Kent M.

AU - Bryant, Susan

AU - Kattine, Anthony A.

AU - Fitzgibbon, James F.

AU - Googe, Paul

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Gonadotropin-releasing hormone analog therapy is useful in treating uterine and some extrauterine smooth muscle tumors. These smooth muscle tumors have been demonstrated to have estrogen receptor and progesterone receptor immunoreactivity. The estrogen receptor and progesterone receptor immunoreactivity of smooth muscle tumors of the skin has not been reported. We evaluated 15 examples of cutaneous leiomyomas for estrogen receptor and progesterone receptor with ER-1D5 antibody and PGR-1AG antibody. None of the 15 cutaneous leiomyomas demonstrated positive staining by this method. The tumorigenesis of cutaneous leiomyomas does not appear to be related to estrogen or progesterone receptor-mediated effects.

AB - Gonadotropin-releasing hormone analog therapy is useful in treating uterine and some extrauterine smooth muscle tumors. These smooth muscle tumors have been demonstrated to have estrogen receptor and progesterone receptor immunoreactivity. The estrogen receptor and progesterone receptor immunoreactivity of smooth muscle tumors of the skin has not been reported. We evaluated 15 examples of cutaneous leiomyomas for estrogen receptor and progesterone receptor with ER-1D5 antibody and PGR-1AG antibody. None of the 15 cutaneous leiomyomas demonstrated positive staining by this method. The tumorigenesis of cutaneous leiomyomas does not appear to be related to estrogen or progesterone receptor-mediated effects.

UR - http://www.scopus.com/inward/record.url?scp=0030935717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030935717&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0560.1997.tb01588.x

DO - 10.1111/j.1600-0560.1997.tb01588.x

M3 - Article

VL - 24

SP - 241

EP - 245

JO - Journal of Cutaneous Pathology

JF - Journal of Cutaneous Pathology

SN - 0303-6987

IS - 4

ER -